These results lead to the prediction that those ovarian carcinomas that express only low levels of CLDN3 and CLDN4 will have greater aggressiveness and metastatic propensity, and that disabling TJ function in those that express high levels of these proteins will launch an EMT and result in a more mesenchymal phenotype. The gene discussed is CLDN4; the disease is ovarian carcinoma.